Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by LITHIUMANon Nov 04, 2016 12:14pm
100 Views
Post# 25425263

NEWS

NEWS

GeneNews Acquires Full Control of Innovative Diagnostic Laboratory

TORONTO, March 04, 2016 (GLOBE NEWSWIRE) -- GeneNews Limited (“GeneNews” or the “Company”) (TSX:GEN) today announced that it has entered into a Unit Purchase Agreement (the “Purchasing Agreement”) with Cobalt Healthcare Consultants, Inc. (“Cobalt”), pursuant to which GeneNews’ wholly- owned subsidiary, GeneNews (USA), Inc., will acquire Cobalt’s fifty percent (50%) ownership interest in the Innovative Diagnostic Laboratory, LLP (“IDL”) joint-venture. Once concluded, GeneNews will have full ownership of IDL.

Under terms of the Purchasing Agreement, GeneNews will assume any and all of Cobalt’s liability relating to Cobalt’s $US 1 million Secured Demand Promissory Note (the “Note”) payable to former IDL partner, HDL USA Holdings, LLC. No other consideration will be paid. Additionally, GeneNews has asked for and received a one year extension on the term of the Note, making it due in May 2017. The Purchasing Agreement is subject to GeneNews completing a strategic financing during March 2016.

“In recent months, we have taken a number of important steps to get the Company on a more solid footing to support an orderly restructuring of its operations,” said GeneNews’ Executive Chairman, James Howard-Tripp. “With a number of difficult decisions behind us, and this Purchasing Agreement in place, we are now much better prepared to pursue the working capital we need to restore IDL’s corporate viability and re-establish its growth trajectory.” 


Bullboard Posts